Presentation is loading. Please wait.

Presentation is loading. Please wait.

Laboratory of Immunobiochemistry Site Visit Ronald L. Rabin, MD FDA/CBER/OVRR/DBPAP November 4, 2010.

Similar presentations

Presentation on theme: "Laboratory of Immunobiochemistry Site Visit Ronald L. Rabin, MD FDA/CBER/OVRR/DBPAP November 4, 2010."— Presentation transcript:

1 Laboratory of Immunobiochemistry Site Visit Ronald L. Rabin, MD FDA/CBER/OVRR/DBPAP November 4, 2010

2 2/25 Laboratory of Immunobiochemistry (LIB) LIB supports the regulatory mission of CBER and FDA in assuring the safety and efficacy of allergenic products in the US original research directed research projects expert advice lot release data BLA and IND review

3 3/25 History of LIB Laboratory of Allergenic Products, Division of Bacterial Products Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology Allergenic Products Testing Lab Allergenic Products Research Lab Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products

4 4/25 Natural allergen extracts Complex mixtures of allergenic proteins, based largely on an unselective aqueous extraction of natural source material (pollens, insects, animals, foods, venoms) Used for Diagnosis (allergy skin testing) and Allergen immunotherapy Documented efficacy in the immunotherapy of allergic disease due to hymenoptera, ragweed, grass, cat, and dust mite allergen exposure

5 5/25 Natural allergen extracts Non-standardized products (n > 1000) Unitage uninformative (PNU/mL or w/v) Standardized products (n = 19) unitage correlates to biological potency mass units, BAU/mL, specific allergen controlled for potency and stability based on identity to US standard constitute a small minority of product number, but a greater percentage of product volume

6 6/25 How can we improve the use of natural allergen extracts? Increase the number of standardized products Improve the standardization of some current products by improving the definition of the measured allergens Increase purity standards selective extraction techniques, purification Improve characterization methods

7 7/25 R ecombinant / engineered allergens Current: Potent research tools dissect immune responses modify immune responses study allergen structure determine structure-function relationships generate novel products

8 8/25 R ecombinant/engineered allergens Opportunities (positive): Allergenicity  immunogenicity Possible standardization tools Greater purity and consistency of product Greater product stability (both due to purity and engineering) Improve delivery systems (in ways not possible using native proteins) Opportunities (negative): Challenges to standardization allergenicity  immunogenicity  potency unique products with different biological features Indications will be very specific IT products may be ineffective for diagnosis Diagnostic products may be ineffective for IT Usage may be population- specific

9 9/25 The last dedicated site visit for LIB was in June 2006 relevant to the mission of the laboratory and deserved continued support from the agency

10 10/25 Staffing Ronald L. Rabin, MD – Lab Chief Philippa Hillyer, Ph.D. Ashraf El Fiky MD, Ph.D.-Visiting Associate Zeng Zhao, MD, Visiting Associate Jay Slater, MD – Supervisory Medical Officer Taruna Khurana, Ph.D. Regulatory Staff Sandra Menzies, MS–Consumer Safety Officer Cherry Valerio Katia Dobrovolskaia Aaron Chen MS Mona Febus

11 11/25 LIB regulatory activities (see Briefing Document, pp.12 - 13) Lot release US reference standards distribution maintenance Regulatory review IND applications BLA applications and supplements Implementation of category IIIA product reclassification to re-evaluate over 1200 non-standardized prodcuts for efficacy ISO (International Standards Organization) 17025 compliance for accreditation to ensure stringent documentation and protocols for SOP Replace RID for Fel d1 and Amb a1 (cat and ragweed) with ELISA 13 th Int’l Paul-Ehrlich-Seminar: Regulatory Control and Standardization of Allergenic Extracts. Washington, D.C. September, 2011

12 12/25 Scientific goals Multiplex allergen extract potency assay characterization of complex allergen extracts Biological activity and expression patterns of subtypes of types I and III IFN Allergen structure and function Modifying allergic responses Extract characterization Endotoxins in allergen extracts

13 Regulatory correlates of LIB’s research program (see Briefing Document, p.15) Regulatory responsibilityResearch correlate Improved lot release capabilities for current and future products Allergen standardization Immunomodulatory approach to inner city asthma Multiplex allergen extract potency; cockroach allergen standardization Allergenic extract safety and efficacy Endotoxin Parameters of effective immunomodulation Types I and III IFN Novel approaches to immunotherapy

Download ppt "Laboratory of Immunobiochemistry Site Visit Ronald L. Rabin, MD FDA/CBER/OVRR/DBPAP November 4, 2010."

Similar presentations

Ads by Google